HDAC6 and lymphoma: For instance, the use of the HDAC6-selective inhibitor ACY1215 (also named rocilinostat or ricolinostat) as a regimen for relapsed or refractory lymphoma and MM is currently in phase I/II clinical trials [Lymphoma (NCT02091063), MM (NCT01323751, NCT01583283, NCT01997840)].